ReviewInternational ophthalmology2025
Artificial intelligence-driven diagnosis for age-related macular degeneration bridging pathology and engineering: a survey.
Review in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related macular degeneration (AMD) is the primary reason for severe visual impairments, making early diagnosis critically important. This paper provides a comprehensive review of the methods used to support screening and diagnostic decisions, focusing on four categories: early, intermediate, and advanced stages of AMD, in addition to AMD across all stages. In this regard, a reference framework is initially proposed to describe research perspectives in pathology. Utilizing this framework, a literature review is conducted to identify the most reliable demographic, environmental, and comorbidity-related risk factors, clinical symptoms, and various aspects of AMD pathology, setting the necessary prerequisites for subsequent sections. The potential application of risk factors is also explained for personalized medicine. While phenotypic risk factors and genetic variants play a crucial role in predicting the progression of AMD, it is more vital to examine demographic and environmental factors at earlier stages for developing effective prevention plans. Therefore, the selection of appropriate risk factors emerges as a critical area of research. Afterward, we present a comparative analysis of different screening and diagnostic methods pertinent to AMD from an industrial engineering perspective. This analysis brings attention to the suite of artificial intelligence (AI) to describe, analyze, and evaluate diagnostic models, thereby providing a reference outline for clinical practice. AI methods can automate the interpretation of retinal images, serving as a supportive tool for clinical decision-making to improve the management of disease progression. In general, this survey highlights the necessity of developing more integrated methods to support decisions at different planning levels.
Indexed as
Identifiers
41182446What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.